Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Other Income (Expense)

Other Income (Expense) at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$160K-95.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
RFL
Rafael Holdings, Inc.RFL
-$25K-116%
XER
Xeris Biopharma Holdings, Inc.XERS
-$36.27M-466%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$3.01M+221%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$7.12M+10.0%

Segments

By segment

See full
Reportable Segment-$6.99M-105%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$705.48M+12.4%
Enterprise value$561.65M-12.6%
P/E12.1×-225×
P/S5.2×-4.9×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Fair value adjustment related to warrant and CVR liability(6,408)(747)(5,440)4,127
Fair value adjustment related to investments(140)(2)(356)(5)
Interest and other income, net2,5652,3786,1552,921
Total other (expense) income(3,983)147,945(11,324)151,390
Income before income taxes12,79476,90657,59974,989
Income tax expense(4,042)(2,199)(10,957)(3,381)
Net income$8,752$74,707$46,642$71,608
Net income per share of common stock:

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s other income (expense)?
Zevra Therapeutics, Inc. (ZVRA) reported other income (expense) of -$3.98M in Q2 2026.
How has Zevra Therapeutics, Inc.'s other income (expense) changed year-over-year?
Zevra Therapeutics, Inc.'s other income (expense) decreased by 102.7% year-over-year, from $147.95M to -$3.98M.
What is the long-term trend for Zevra Therapeutics, Inc.'s other income (expense)?
Over 3 years (2021 to 2025), Zevra Therapeutics, Inc.'s other income (expense) has grown at a 108.9% compound annual growth rate (CAGR), from -$16.42M to $149.62M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Zevra Therapeutics, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude